CHARLOTTESVILLE, Virginia, December 2, 2015 /PRNewswire/ — Biovista announced today that it has entered into a drug repositioning collaboration with Astellas Pharma Inc. The collaboration is focused on identifying new indications for a number of undisclosed Astellas compounds using Biovista’s Clinical Outcome Search Space (COSS) technology. “We look forward to working with the Drug Repurposing … Read More
Year: 2015
Biovista Sponsors Wylder Nation Foundation’s Research on Acid Sphingomyelinase Deficiency
CHARLOTTESVILLE, Virginia, September 2, 2015 /PRNewswire/ — Biovista Inc. is glad to announce the sponsoring of the winners of the 2015 BeHEARD science challenge, a global competition hosted by the Rare Genomics Institute that offers rare disease researchers, access to the latest life science innovations and technologies.
How to develop differentiated therapies cost effectively: NCEs, repositioned drugs or both?
Andreas Persidis, CEO Everybody agrees that the success of a drug increasingly depends on the total value it delivers. The commercial performance to date of Lundbeck’s antidepressant Brintellix is a case in point. Having demonstrated statistically significant efficacy over placebo in study results reported in 2012, Brintellix was approved by the FDA in 2013. Brintellix’s … Read More
New Biovista Inc. Publication: EMR Data Confirm Big Data Analytics Prediction That Hypothyroidism is a Risk Factor for New-onset Diabetes Mellitus
CHARLOTTESVILLE, Virginia, June 23, 2015 /PRNewswire/ — Biovista Inc. today announced the publication of data from research it carried out in collaboration with the FDA and Israeli HMO Clalit, focusing on the prediction of risk factors related to targeted diseases. The research, published in the American Diabetes Association journal Diabetes Care, identifies hypothyroidism as a … Read More
Can drug development learn from Apple’s Music strategy?
Apple’s strategy for its Apple Music service may offer an apt analogy to help us reframe the therapy research and development enterprise.
12